Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | ESRRA | P11474 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369984 | 0.85 | SLC6A4 (0.54) | FNTBARKCNH2SLC6A4SLC6A3 | |
| SCHEMBL12096582 | 0.81 | AR (0.54) | ARKCNH2SLC6A4SLC6A3HTR2A | |
| SCHEMBL2402612 | 0.80 | PPARD (0.43) | SIGMAR1HRH1FNTBARKCNH2 | |
| SCHEMBL12096613 | 0.80 | PTGDR (0.42) | SIGMAR1HRH1FNTBSLC6A4PPARD | |
| SCHEMBL12096570 | 0.80 | PTGDR (0.42) | SIGMAR1HRH1FNTBSLC6A4PPARD | |
| SCHEMBL12096575 | 0.80 | PTGDR (0.42) | SIGMAR1HRH1FNTBSLC6A4PPARD | |
| SCHEMBL2400201 | 0.77 | KCNH2 (0.39) | SIGMAR1HRH1FNTBARKCNH2 | |
| SCHEMBL10064488 | 0.77 | PTGDR (0.40) | SIGMAR1HRH1FNTBARPPARD | |
| SCHEMBL15163377 | 0.77 | PPARD (0.36) | SIGMAR1HRH1FNTBKCNH2SLC6A4 | |
| SCHEMBL2402520 | 0.77 | PPARD (0.36) | SIGMAR1HRH1FNTBKCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759564-B2 | Amidoacetonitrile compounds having pesticidal activity | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2503882-B1 | AMIDOACETONITRILE COMPOUNDS HAVING PESTICIDAL ACTIVITY | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-2373162-B1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20120232138-A1 | AMIDOACETONITRILE COMPOUNDS HAVING PESTICIDAL ACTIVITY | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8168681-B2 | Amidoacetonitrile compounds and pesticidal composition thereof | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232138-A1 | AMIDOACETONITRILE COMPOUNDS HAVING PESTICIDAL ACTIVITY | ACHE, NAAA, NIT2 | SIGMAR1 4662/4885HRH1 2196/4885FNTB 940/4885 |
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NAAA, PTMS, NIT2 | SIGMAR1 4696/4885HRH1 2763/4885FNTB 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.